JOHNS HOPKINS UNIVERSITY

🇳🇦Namibia

Country: 🇳🇦Namibia

Ownership: -

Established: 1876-01-01

Employees: 19.4K

Market Cap: -

Website: https://www.jhu.edu/

Clinical Trials

Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

Phase 2

Terminated

Conditions: Tuberculosis

Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid
Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol

First Posted Date: 2008-08-05

Last Posted Date: 2017-04-20

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 121

Registration Number: NCT00728507

Locations: 🇧🇷
Posto de Saude Albert Sabin, Rio de Janeiro, RJ, Brazil
🇧🇷
Hospital Universitario Clementio Fraga Filho, Rio de Janeiro, Brazil
🇧🇷
Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ, Curicica, Rio de Janeiro, Brazil

Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia

Not Applicable

Withdrawn

Conditions: Ventricular Tachycardia

Interventions: Drug: Increased dose of amiodarone
Procedure: MRI guided VT ablation

First Posted Date: 2008-07-23

Last Posted Date: 2017-05-10

Lead Sponsor: Johns Hopkins University

Registration Number: NCT00721032

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

Not Applicable

Completed

Conditions: Tachycardia
Atrial Fibrillation
Valvular Heart Disease
Bradycardia

Interventions: Drug: continue warfarin through the procedure
Drug: Hold warfarin
Drug: Warfarin held with heparin transition.

First Posted Date: 2008-07-23

Last Posted Date: 2017-08-31

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 104

Registration Number: NCT00721136

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸
Howard County General Hospital, Columbia, Maryland, United States

Efficacy of Losartan in Preventing Progression of COPD

Phase 4

Completed

Conditions: Emphysema
COPD
Chronic Bronchitis
Smoking

Interventions: Drug: Placebo
Drug: Losartan

First Posted Date: 2008-07-22

Last Posted Date: 2017-04-25

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 106

Registration Number: NCT00720226

Locations: 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States

Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials

Completed

Conditions: Respiratory Distress Syndrome, Adult

First Posted Date: 2008-07-21

Last Posted Date: 2015-09-01

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 922

Registration Number: NCT00719446

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Wake Forest University, Winston Salem, North Carolina, United States

and more 3 locations

Simvastatin For Intracerebral Hemorrhage Study

Phase 2

Terminated

Conditions: Intracerebral Hemorrhage

Interventions: Drug: Simvastatin 80 mg
Drug: Placebo

First Posted Date: 2008-07-18

Last Posted Date: 2017-10-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT00718328

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Evaluation of Adolescent Smoking Cessation Programs

Not Applicable

Completed

Conditions: Smoking Status

Interventions: Behavioral: NOT controls
Behavioral: NOT program
Behavioral: Kicking Butts intervention
Behavioral: KB controls

First Posted Date: 2008-07-14

Last Posted Date: 2008-07-14

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 407

Registration Number: NCT00714207

Locations: 🇺🇸
Patterson High School, Baltimore, Maryland, United States
🇺🇸
Hammond High School, Columbia, Maryland, United States
🇺🇸
Southern High School/Digital Harbor, Baltimore, Maryland, United States

and more 5 locations

Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)

Phase 2

Withdrawn

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease

Interventions: Procedure: Patient controlled analgesia
Drug: nurse-administered intermittent IV bolus opioid therapy (NAIBOD)

First Posted Date: 2008-07-09

Last Posted Date: 2017-03-24

Lead Sponsor: Johns Hopkins University

Registration Number: NCT00711698

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India

Phase 2

Withdrawn

Conditions: HIV Infections
Heroin Dependence

Interventions: Behavioral: Directly Administered Antiretroviral Therapy (DAART)
Behavioral: SAT

First Posted Date: 2008-07-03

Last Posted Date: 2015-04-15

Lead Sponsor: Johns Hopkins University

Registration Number: NCT00709007

Locations: 🇮🇳
YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR), Chennai, Tamil Nadu, India

Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness

Not Applicable

Completed

Conditions: Muscle Weakness
Intensive Care Unit

Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)
Device: Sham

First Posted Date: 2008-07-03

Last Posted Date: 2018-01-23

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 36

Registration Number: NCT00709124

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy